These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 30565179)

  • 1. Pan-European Expert Meeting on the Use of Metronomic Chemotherapy in Advanced Breast Cancer Patients: The PENELOPE Project.
    Cazzaniga ME; Munzone E; Bocci G; Afonso N; Gomez P; Langkjer S; Petru E; Pivot X; Sánchez Rovira P; Wysocki P; Torri V
    Adv Ther; 2019 Feb; 36(2):381-406. PubMed ID: 30565179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study.
    Cazzaniga ME; Vallini I; Montagna E; Amoroso D; Berardi R; Butera A; Cagossi K; Cavanna L; Ciccarese M; Cinieri S; Cretella E; De Conciliis E; Febbraro A; Ferraù F; Ferzi A; Baldelli A; Fontana A; Gambaro AR; Garrone O; Gebbia V; Generali D; Gianni L; Giovanardi F; Grassadonia A; Leonardi V; Marchetti P; Sarti S; Musolino A; Nicolini M; Putzu C; Riccardi F; Santini D; Saracchini S; Sarobba MG; Schintu MG; Scognamiglio G; Spadaro P; Taverniti C; Toniolo D; Tralongo P; Turletti A; Valenza R; Valerio MR; Vici P; Di Mauro P; Cogliati V; Capici S; Clivio L; Torri V;
    Breast Cancer Res Treat; 2021 Dec; 190(3):415-424. PubMed ID: 34546500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study.
    Cazzaniga ME; Pinotti G; Montagna E; Amoroso D; Berardi R; Butera A; Cagossi K; Cavanna L; Ciccarese M; Cinieri S; Cretella E; De Conciliis E; Febbraro A; Ferraù F; Ferzi A; Fiorentini G; Fontana A; Gambaro AR; Garrone O; Gebbia V; Generali D; Gianni L; Giovanardi F; Grassadonia A; Leonardi V; Marchetti P; Melegari E; Musolino A; Nicolini M; Putzu C; Riccardi F; Santini D; Saracchini S; Sarobba MG; Schintu MG; Scognamiglio G; Spadaro P; Taverniti C; Toniolo D; Tralongo P; Turletti A; Valenza R; Valerio MR; Vici P; Clivio L; Torri V;
    Breast; 2019 Dec; 48():7-16. PubMed ID: 31470257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Final results of the real-life observational VICTOR-6 study on metronomic chemotherapy in elderly metastatic breast cancer (MBC) patients.
    Trevisan B; Pepe FF; Vallini I; Montagna E; Amoroso D; Berardi R; Butera A; Cagossi K; Cavanna L; Ciccarese M; Cinieri S; Cretella E; De Conciliis E; Febbraro A; Ferraù F; Ferzi A; Baldelli A; Fontana A; Gambaro AR; Garrone O; Gebbia V; Generali D; Gianni L; Giovanardi F; Grassadonia A; Leonardi V; Sarti S; Musolino A; Nicolini M; Putzu C; Riccardi F; Santini D; Sarobba MG; Schintu MG; Scognamiglio G; Spadaro P; Taverniti C; Toniolo D; Tralongo P; Turletti A; Valenza R; Valerio MR; Vici P; Clivio L; Torri V; Cazzaniga ME;
    Sci Rep; 2023 Jul; 13(1):12255. PubMed ID: 37507480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of advanced breast cancer with a metronomic schedule of oral vinorelbine: what is the opinion of Italian oncologists?
    Cazzaniga ME; Munzone E; Montagna E; Pappagallo G
    Expert Rev Anticancer Ther; 2018 Aug; 18(8):805-814. PubMed ID: 29902087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. On and off metronomic oral vinorelbine in elderly women with advanced breast cancer.
    De Iuliis F; Salerno G; Taglieri L; Lanza R; Scarpa S
    Tumori; 2015; 101(1):30-5. PubMed ID: 25702645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metronomic oral vinorelbine in advanced breast cancer and non-small-cell lung cancer: current status and future development.
    Cazzaniga ME; Camerini A; Addeo R; Nolè F; Munzone E; Collovà E; Del Conte A; Mencoboni M; Papaldo P; Pasini F; Saracchini S; Bocci G
    Future Oncol; 2016 Feb; 12(3):373-87. PubMed ID: 26584409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunomodulatory effects of metronomic vinorelbine (mVRL), with or without metronomic capecitabine (mCAPE), in hormone receptor positive (HR+)/HER2-negative metastatic breast cancer (MBC) patients: final results of the exploratory phase 2 Victor-5 study.
    Pepe FF; Cazzaniga ME; Baroni S; Riva F; Cicchiello F; Capici S; Cogliati V; Maggioni C; Cordani N; Cerrito MG; Malandrin S
    BMC Cancer; 2022 Sep; 22(1):956. PubMed ID: 36068484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metronomic Chemotherapy for Metastatic Breast Cancer Treatment: Clinical and Preclinical Data between Lights and Shadows.
    Cazzaniga ME; Capici S; Cordani N; Cogliati V; Pepe FF; Riva F; Cerrito MG
    J Clin Med; 2022 Aug; 11(16):. PubMed ID: 36012949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-targeting triple-negative breast cancer cells and endothelial cells by metronomic chemotherapy inhibits cell regrowth and migration
    Scagliotti A; Capizzi L; Cazzaniga ME; Ilari A; De Giorgi M; Cordani N; Gallazzi M; Bruno A; Pelosi G; Albini A; Lavitrano M; Grassilli E; Cerrito MG
    Front Oncol; 2022; 12():998274. PubMed ID: 36531071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Oral vinorelbine: pharmacology and treatment outcome in non-small cell bronchial carcinoma and breast carcinoma].
    Bartsch V
    Onkologie; 2006 Mar; 29 Suppl 1():1-28. PubMed ID: 16534241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metronomic chemotherapy for advanced breast cancer patients.
    Cazzaniga ME; Dionisio MR; Riva F
    Cancer Lett; 2017 Aug; 400():252-258. PubMed ID: 28017894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
    Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
    Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metronomic therapy in advanced breast cancer and NSCLC: vinorelbine as a paradigm of recent progress.
    Xu B; Sun T; Wang S; Lin Y
    Expert Rev Anticancer Ther; 2021 Jan; 21(1):71-79. PubMed ID: 33054438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study.
    Cazzaniga ME; Cortesi L; Ferzi A; Scaltriti L; Cicchiello F; Ciccarese M; Della Torre S; Villa F; Giordano M; Verusio C; Nicolini M; Gambaro AR; Zanlorenzi L; Biraghi E; Legramandi L; Rulli E;
    Breast Cancer Res Treat; 2016 Dec; 160(3):501-509. PubMed ID: 27752847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity.
    Montagna E; Cancello G; Bagnardi V; Pastrello D; Dellapasqua S; Perri G; Viale G; Veronesi P; Luini A; Intra M; Calleri A; Rampinelli C; Goldhirsch A; Bertolini F; Colleoni M
    Clin Breast Cancer; 2012 Jun; 12(3):207-14. PubMed ID: 22520733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metronomic chemotherapy combined with endocrine therapy: are we challenging some dogmas?
    Caparica R; De Angelis C; Fêde Â; Werutsky G; de Azambuja E
    Expert Rev Anticancer Ther; 2020 Jul; 20(7):563-573. PubMed ID: 32536212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer.
    Saridaki Z; Malamos N; Kourakos P; Polyzos A; Ardavanis A; Androulakis N; Kalbakis K; Vamvakas L; Georgoulias V; Mavroudis D
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):35-42. PubMed ID: 21590447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metronomic Chemotherapy.
    Cazzaniga ME; Cordani N; Capici S; Cogliati V; Riva F; Cerrito MG
    Cancers (Basel); 2021 May; 13(9):. PubMed ID: 34066606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metronomic capecitabine combined with aromatase inhibitors for new chemoendocrine treatment of advanced breast cancer: a phase II clinical trial.
    Li JW; Zuo WJ; Ivanova D; Jia XQ; Lei L; Liu GY
    Breast Cancer Res Treat; 2019 Jan; 173(2):407-415. PubMed ID: 30361875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.